PMID- 32030780
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1398-9995 (Electronic)
IS  - 0105-4538 (Linking)
VI  - 75
IP  - 8
DP  - 2020 Aug
TI  - Artemisia annua-sublingual immunotherapy for seasonal allergic rhinitis: A 
      randomized controlled trial.
PG  - 2026-2036
LID - 10.1111/all.14218 [doi]
AB  - BACKGROUND: Artemisia annua is an important autumnal pollen allergen for seasonal 
      allergic rhinitis (SAR) in northern China. To date, no study has investigated 
      allergen immunotherapy with A annua. We aimed to investigate the efficacy and 
      mechanisms underlying A annua-sublingual immunotherapy (SLIT). METHODS: This was 
      a randomized, double-blind, placebo-controlled phase III clinical trial involving 
      71 SAR patients, randomized to SLIT with A annua extract (n = 47) or placebo 
      (n = 24) for 32 weeks. Total nasal symptom score (TNSS; primary clinical end 
      point) was evaluated at baseline (peak pollen phase (PPP) in the previous year), 
      initiation of A annua-SLIT, 1st PPP during SLIT, end of SLIT and 2nd PPP during 
      follow-up. Blood samples and nasal secretions were collected at beginning and 
      after SLIT for assessment of T cells and inflammatory mediators. Safety was 
      assessed according to adverse events (AEs) reported. RESULTS: Artemisia 
      annua-SLIT significantly reduced TNSS to a greater level from baseline (from 
      9.45 +/- 1.68 to 6.16 +/- 2.27) than placebo (from 9.29 +/- 2.09 to 9.05 +/- 2.40) at the 
      1st PPP (P < .001) and sustained the improvement in symptoms throughout to the 
      2nd PPP. Preseasonal A annua-SLIT for 16 weeks significantly decreased Th2 cells, 
      increased nTreg and Tr1 cells in blood; and increased cystatin 1 (CST1) in nasal 
      secretion after 16 and 32 weeks compared with pretreatment. Overall, 17/47 
      patients experienced mild local AEs and 2 patients mild systemic AEs, after 
      A annua-SLIT. CONCLUSION: Artemisia annua-SLIT is an efficacious and safe 
      treatment in patients with A annua SAR.
CI  - (c) 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
FAU - Lou, Hongfei
AU  - Lou H
AUID- ORCID: 0000-0002-8553-812X
AD  - Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital, 
      Capital Medical University, Beijing, China.
AD  - Beijing Key Laboratory of Nasal Disease, Beijing Institute of Otolaryngology, 
      Beijing, China.
FAU - Huang, Yanran
AU  - Huang Y
AUID- ORCID: 0000-0001-5755-7684
AD  - Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital, 
      Capital Medical University, Beijing, China.
AD  - Beijing Key Laboratory of Nasal Disease, Beijing Institute of Otolaryngology, 
      Beijing, China.
FAU - Ouyang, Yuhui
AU  - Ouyang Y
AUID- ORCID: 0000-0002-5946-0779
AD  - Beijing Key Laboratory of Nasal Disease, Beijing Institute of Otolaryngology, 
      Beijing, China.
AD  - Department of Allergy, Beijing TongRen Hospital, Capital Medical University, 
      Beijing, China.
FAU - Zhang, Yuan
AU  - Zhang Y
AUID- ORCID: 0000-0003-1080-4267
AD  - Beijing Key Laboratory of Nasal Disease, Beijing Institute of Otolaryngology, 
      Beijing, China.
AD  - Department of Allergy, Beijing TongRen Hospital, Capital Medical University, 
      Beijing, China.
FAU - Xi, Lin
AU  - Xi L
AUID- ORCID: 0000-0003-0028-6873
AD  - Beijing Key Laboratory of Nasal Disease, Beijing Institute of Otolaryngology, 
      Beijing, China.
AD  - Department of Allergy, Beijing TongRen Hospital, Capital Medical University, 
      Beijing, China.
FAU - Chu, Xiaohan
AU  - Chu X
AUID- ORCID: 0000-0001-6045-175X
AD  - Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital, 
      Capital Medical University, Beijing, China.
AD  - Beijing Key Laboratory of Nasal Disease, Beijing Institute of Otolaryngology, 
      Beijing, China.
FAU - Wang, Yang
AU  - Wang Y
AUID- ORCID: 0000-0003-1231-7278
AD  - Beijing Key Laboratory of Nasal Disease, Beijing Institute of Otolaryngology, 
      Beijing, China.
FAU - Wang, Chengshuo
AU  - Wang C
AUID- ORCID: 0000-0003-0646-5135
AD  - Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital, 
      Capital Medical University, Beijing, China.
AD  - Beijing Key Laboratory of Nasal Disease, Beijing Institute of Otolaryngology, 
      Beijing, China.
FAU - Zhang, Luo
AU  - Zhang L
AUID- ORCID: 0000-0002-0910-9884
AD  - Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital, 
      Capital Medical University, Beijing, China.
AD  - Beijing Key Laboratory of Nasal Disease, Beijing Institute of Otolaryngology, 
      Beijing, China.
AD  - Department of Allergy, Beijing TongRen Hospital, Capital Medical University, 
      Beijing, China.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200223
PL  - Denmark
TA  - Allergy
JT  - Allergy
JID - 7804028
RN  - 0 (Allergens)
SB  - IM
MH  - Allergens
MH  - *Artemisia annua
MH  - China
MH  - *Conjunctivitis, Allergic
MH  - Desensitization, Immunologic
MH  - Double-Blind Method
MH  - Humans
MH  - *Rhinitis, Allergic, Seasonal/therapy
MH  - *Sublingual Immunotherapy
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Artemisia annua
OT  - allergen immunotherapy (AIT)
OT  - allergic rhinitis
OT  - efficacy
OT  - safety
EDAT- 2020/02/08 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/02/08 06:00
PHST- 2019/08/11 00:00 [received]
PHST- 2019/11/17 00:00 [revised]
PHST- 2019/12/08 00:00 [accepted]
PHST- 2020/02/08 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/02/08 06:00 [entrez]
AID - 10.1111/all.14218 [doi]
PST - ppublish
SO  - Allergy. 2020 Aug;75(8):2026-2036. doi: 10.1111/all.14218. Epub 2020 Feb 23.